Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...

Improved Linker and Payload Selection: The selection of suitable linkers and cytotoxic payloads greatly impacts ADC stability, efficacy, and safety. Next-generation ADCs aim to employ novel linkers ...

The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...

Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports. In the recent years, antibody-drug conjugates (ADC) have been gradually gaining ...

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats Traditional ADCs have seen significant success in ...

ADCs are a drug platform consisting of an antibody, a cytotoxic payload, and a linker molecule designed to enhance the therapeutic index and minimize toxicity of anticancer agents. Optimal patient ...

The 3rd Next-Generation Conjugates Summit (Boston | February 26-28, 2024) is the only event dedicated to showcasing conjugate drugs with novel payloads and formats, providing unrivalled access to 30+ ...